

The
Microbiology
NETWORK

FDA and the Compounding Pharmacy

Scott Sutton, Ph.D.
scott.sutton@microbiol.org

www.microbiol.org

The background of this slide features a blue-tinted, close-up image of various bacteria, including rod-shaped and spherical forms, set against a dark background.

Overview of Presentation

- The Recent Events
- GCP and GMP Basics – the 483 Review
- H.R. 3204 – Outsourcing Facility
- Preparation for the Future

BioNeutral Group

- Disinfection and sterilization is a timely topic for Compounding Pharmacies
- BioNeutral launched our YGIENE 206 Sporicidal/Disinfectant earlier this year
- Good success:
 - Research facilities
 - GMP pharmaceutical manufacturing
 - Compounding pharmacies

BIONEUTRAL
Advanced Infection Control

YGIENE 206 Sporicidal/Disinfectant

- Oxidative chemistry (H_2O_2 +PAA)
 - “Kills most” in 90 – 120 seconds
 - “Kills all” – fastest EPA registered sterilant(20 min.)
- Excellent materials compatibility
 - Gentle on stainless steel and other surfaces
 - Relatively pH neutral (4 -5)
 - Environmentally friendly
- Contact Ray Dunning – 440 799 7701
Ray.d@bionutral.com

BIONEUTRAL
Advanced Infection Control

Disclaimer

- I am making this presentation as an independent agent
- I am not making this presentation as a representative of USP, PDA, PMF or any other organization with which I am currently associated.
- The views expressed in this presentation are offered as mine alone.

Overview of Presentation

- The Recent Events
- GCP and GMP Basics – the 483 Review
- H.R. 3204 – Outsourcing Facility
- Preparation for the Future






Table 1. Issues in Compounding Pharmacies Identified by FDA 483 Observations*

	SOPs to Prevent Microbial Contamination Non-existent or Not Followed	Inadequate/Improper EM	Stability Program	Inadequate Gowning	Batch Release	Validation of Sterilization	Lab Procedures: Testing/Contract Lab Control
Anashealth	1*	4	8	5	3	2	11
Avella of Deer Valley	3	2	-	1	6	4	-
Balanced Solutions Compounding	3	4	9	6	1,7	5	-
CAPS (Central Admixure Pharmacy Services) (Chicago)	-	2	7	3	1	6	-
CAPS (Homewood, AL)	6	6	9,12	4	1,2	-	11
CAPS (Kansas City)	2	3	-	2	4	-	3
CAPS (Livonia)	3,5	-	-	-	6	-	-
College Pharmacy, Inc.	-	1	5	-	2,6	4	2
Compounding Shop, The	1	2	11	9	4,10	5	4
Drugs Are Us	-	1	3	2	-	-	-
Foundation C	-	-	-	-	-	-	-
Home Int	-	-	-	-	-	-	-
IV Solutions	-	-	-	-	-	-	-
Lee Pharm	-	-	-	-	-	-	-
Lowly P	-	-	-	-	-	-	-
Medaus	-	-	-	-	-	-	-
Medi-Far Center	-	-	-	-	-	-	-
NECC	-	-	-	-	-	-	-
Nota App	-	-	-	-	-	-	-
Therapie	-	-	-	-	-	-	-
Oakdell P	-	-	-	-	-	-	-
Olympia Pharm	-	-	-	-	-	-	-
Pentac Health	8	-	6	2	-	1	5
PharMEDium Services (Cleveland)	5	-	10,11	-	3,9	3	2,3,9
PharMEDium Services (Edison, NJ)	5	-	4	1	3	-	2
PharMEDium Services (Memphis, TN)	3	-	8,12	-	5,7	6	4,5
PharMEDium Services (Sugarland, TX)	3	8	6,7,9	2	4,5	-	4
Portage Pharmacy	1	3	10,11	4	2,6,7,8	-	9,12
Specialty Compounding	1	3	5	2	7	4	6
Triangle Compounding	4	3	-	-	-	2	-
University Pharmacy	4	5	6	-	2	3	-
Wedgewood Village Pharmacy	-	-	-	1	3,10	4	3,9

Sutton, S. 2013. GMP and Compounding Pharmacies. *Amer Pharm Rev.* 16(3):48-59.
<http://www.americanpharmaceuticalreview.com/Featured-Articles/135985-GMP-and-Compounding-Pharmacies/>





The Press

Table 2. Compounding Pharmacies and Microbial Contamination in the News*

2012	<ul style="list-style-type: none"> 33 people across 7 states contracted fungal endophthalmitis leading to the recall of 6 month's worth of all compounded butabine from Francis Pharmacy. This pharmacy also produces valproic products (MVA of 2005 cases). http://www.cdc.gov/media/releases/2012/s120228.html Chlo-Basear lubricant (a non-sterile product) was recalled due to potentially pathogenic microbial contamination. http://www.fda.gov/oc/ohrt/2012/12/07/4060-assa/chlo-basear-lubricant-art-saline-due-microbial-contamination/ As of February 4, 2014 687 patients contracted fungal meningitis after receiving methyl-Prethiolone acetate injection prepared by RECC (the current originator to compounding pharmacies) http://www.cdc.gov/media/releases/2014/s020414.html
2011	<ul style="list-style-type: none"> 9 patients died of the 10 total taken ill in Alabama when parenteral nutrition solutions that were administered were contaminated with <i>Serratia marcescens</i> during compounding using non-sterile components to prepare amino acids. The compounding pharmacy, Meds N, was found to have the same strain of <i>S. marcescens</i> in the tap water faucet and the compounding equipment. http://www.cdc.gov/media/releases/2011/s093011.html 14 people in Florida and Tennessee infected when a compounding pharmacy in Hollywood, CA packaged Avastin for off-label eye injections. Contaminated intra-ocular injections for age-related macular degeneration resulted in blindness for some. http://www.nytimes.com/2011/08/31/health/31drug.html?_r=36
2007	<ul style="list-style-type: none"> Eight cases of <i>Sphingomonas paucimobilis</i> bloodstream infections were associated with contaminated intravenous teniposide. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1489171/
2005	<ul style="list-style-type: none"> Up to 25 patients in New Jersey and California contracted <i>Serratia marcescens</i> infections due to contaminated magnesium sulfate prepared by Pharmedex, a compounding pharmacy located in Lake Forest, IL. http://www.cdc.gov/media/releases/2005/s072805.html 4 cases of post-surgical endophthalmitis were reported due to a compounded triamcinolone injection contaminated with <i>Pseudomonas aeruginosa</i> and <i>Haemophilus</i> species. This was recalled by the compounding pharmacy Custom Rx of Rockport, MN. http://www.cdc.gov/media/releases/2005/s071105.html 18 patients died in Virginia after exposure to cardioplegia solution from 2 lots contaminated with gram-negative rods. The product was made by Central Administrative Pharmacy Services, Inc. (CAPS), a subsidiary of B. Braun Medical located in Maryland (also see 1998 incident below). http://www.cdc.gov/media/releases/2005/s062205.html <i>Pseudomonas</i> patient septicemia was reported in a special care nursery due to contaminated flush solutions prepared in a hospital pharmacy. http://www.cdc.gov/pmc/articles/PMC1248510/ 26 cases of <i>Pseudomonas fluorescens</i> bloodstream infections were associated with a heparin saline flush. From the MMWR Report: "The product is heparin saline flush, IV flush solution heparin powder and salt kit, a compounding pharmacy, where a concentrated heparin solution was made. This concentrated solution was then returned to IV flush, where it was added to bags of saline solution, from which the syringes were filled." IV flush was located in Rowlett, Texas while the affected patients were in four states across the country. A peer research paper identified potentially 89 cases. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5411a1.htm
2004	<ul style="list-style-type: none"> 34 patients developed <i>Pseudomonas</i> bloodstream infections after receiving heparin saline flushes from multiple lots of prepackaged syringes by Fresenius Medical Supply of Rowlett, TX. These infections occurred in Missouri, New York, Texas, and Michigan. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5411a1.htm 2 patients reported with the intravitreal injection caused by <i>Burkholderia cepacia</i> from contaminated intravenous flush solutions that had been shipped across state lines. http://pediatrics.aappublications.org/content/115/1/e22.html 14 patients were reported with Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5411a1.htm
2003	<ul style="list-style-type: none"> Multiple contamination with <i>Burkholderia</i> species was found in at least 3 batches of a compounded heparin solution used by 10,000 patients nationwide with chronic lung disease. Med 4 Home (Kansas City, MO) did only a partial recall of the batches, which totaled more than 1 million doses. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5411a1.htm
2002	<ul style="list-style-type: none"> MMWR report on <i>Escherichia coli</i> (O157:H7) infections from contaminated injectable methyl-Prethiolone prepared by a compounding pharmacy; one patient died. NOTE that the report describes fungal meningitis from a stored glass injection. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5315a1.htm Injectable methylprednisolone and baclofen was recalled by FDA recommendation because of contamination with <i>Penicillium mold</i>, <i>Aspergillus</i>, and/or <i>Mycobacterium chelonae</i>. The recall was later expanded to all products of Urgent Care Pharmacy due to poor manufacturing quality. http://www.fda.gov/oc/ohrt/2002/02/04/44.html
2001	<ul style="list-style-type: none"> 11 patients contracted <i>Serratia marcescens</i> infections following the injection of betamethasone compounded at a community pharmacy in California. http://www.ncbi.nlm.nih.gov/pubmed/11644132 4 children contracted <i>Enterobacter cloacae</i> infections from IV cartons compounded in a hospital pharmacy. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm520202b.htm 13 patients (3 fatalities) came down with bacterial meningitis after receiving contaminated betamethasone shots prepared by Dico Pharmacy in California. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm520202b.htm MedAlert Pulmonary Services of California was forced to recall five lots of Albuterol (an inhalant) due to contamination by <i>Serratia marcescens</i>. http://www.zdnet.com/news/med-alert-pulmonary-services-of-california-was-forced-to-recall-five-lots-of-albuterol-an-inhalant-due-to-contamination-by-serratia-marcescens-307372197.html
1999	<ul style="list-style-type: none"> Survey of compounded Alprostadil formulations from a variety of sources showed contamination in 11% of samples tested. http://www.jgim.com/abstracts/abstract_cfm?AB=684
1998	<ul style="list-style-type: none"> 11 children became septic in California and 10 tested positive for <i>Enterobacter cloacae</i> bloodstream infections associated with contaminated prefilled saline syringes from CPCS, Branford, New York. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm470505a1.htm
1990	<ul style="list-style-type: none"> Four patients died of an <i>Enterobacter</i> infection from a multi-dose cardioplegia solution (a parenteral) with high potential for bacteremia) compounded in a Nebraska hospital. In this episode the bottle of the solution tested was non-sterile, several subsequent bottles tested were sterile, and another 83 bottles were dispensed without being tested. http://www.jgim.com/abstracts/abstract_cfm?AB=684 2 patients lost their vision after becoming infected by <i>Pseudomonas aeruginosa</i> found in indomethacin eye drops compounded in a Pennsylvania drug store. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm470505a1.htm



Overview of Presentation

- The Recent Events
- GCP and GMP Basics – the 483 Review
- H.R. 3204 – Outsourcing Facility
- Preparation for the Future



Stability Program

- A lack of data supporting the potency, sterility (or occasionally any data whatsoever) of the preparation that might be stored for over a year.
- Clearly this is a GCP concern (well beyond BUD as described in <797>) as well as a GMP concern for compounding manufacturers

Validation of Sterilization - Media Fills

- Terminally sterilized preparations were not subjected to a validated sterilization cycle in an autoclave
- Or an aseptic fill operations not validated by a relevant media fill (simulated aseptic fill).

<797> discusses this consideration in the section "Verification of Compounding Accuracy and Sterility – Sterilization Methods – Sterilization of High-Risk Level CSPs by Steam" where it is stated "The description of steam sterilization conditions and duration for specific CSPs is included in written documentation in the compounding facility. The effectiveness of steam sterilization is verified using appropriate biological indicators (see Biological Indicators <1035>) or other confirmation methods (see Sterilization and Sterility Assurance of Compendial Articles <1211> or Sterility Tests <71>)

Inadequate/Improper Environmental Monitoring

- Wide range of issues with environmental monitoring (EM) from insufficient frequency, failure to qualify sampling sites, failure to trend data, failure to respond to excursions, etc).
- This area is one of divergence between GCP (<795>, <797> and <1163>) and GMP as the expectations of GMP are designed to address manufacturing facilities, not the compounding pharmacy.

SOPs to Prevent Microbial Contamination Non-existent or Not Followed

- Wide range of specific issues such as
 - failure to have a qualified sanitization (or in some cases any sanitization) program
 - failure to have cleaning/sanitization procedure
 - having procedures but ignoring them in practice, *etc.*

This is clearly both a GCP and GMP issue as there are multiple references in both <795> and <797> to activities designed to control, monitor and minimize microbial contamination.

Inadequate Gowning

- Lack of critical pieces of gowns (hairnet, beard covers, foot covers, etc)
- Having gaps in gowns
- Poor gowning technique
- Poor aseptic technique with gowns.

This GCP concern is covered in USP<797> section “Additional Personnel Requirements – Personnel Cleansing and Garbing”

Lab Procedures: Testing/ Contract Lab Control

- Poor or non-compliant performance of required testing
 - Potency Testing
 - Sterility Testing
 - Method Suitability
 - Inadequate sample volume
 - Inadequate incubation duration
 - Incorrect incubation temperatures
 - Incorrect growth media
- Poor oversight of testing labs

Batch Release

Release of sterile product under improper conditions without either potency testing, sterility testing, or perhaps any testing whatsoever to confirm the preparation's strength, purity, quality or safety.

Inadequate Cleaning/Disinfection

- Manufacturing equipment or the facility cleanliness and the failure of the pharmacy to ensure that there was no carry-over of preparations from one batch to the next
- Failure to confirm that the disinfection of the aseptic area and PEC were actually working.

The GCP requirements for this issue are discussed in USP <797> in the sections "Cleaning and Disinfecting the Compounding Area"

Control of Equipment

Failure of the pharmacy to ensure that the equipment used for compounding was fit for its intended use.

This GCP topic is discussed in the section "Elements of Quality Control – Equipment" where it is stated "...equipment, apparatus, and devices used to compound a CSP be consistently capable of operating properly and within acceptable tolerance limits. Written procedures outlining required equipment calibration, annual maintenance, monitoring for proper function, and controlled procedures for use of the equipment and specified time frames for these activities are established and followed."

Inadequate Facility / Smoke Studies

These observations dealt with adequacy of design and qualification studies to ensure the facility is meeting expectations for air balance and air flow in aseptic areas.

USP <797> does expect air pressure differentials of 0.02 to 0.05-inch water column between rooms providing physical separation in the aseptic core and that "In situ air pattern analysis via smoke studies should be conducted at the critical area to demonstrate unidirectional airflow and sweeping action over and away from the product under dynamic conditions" (see section "Facility Design and Environmental Controls").

Investigations

Inadequate response to problems or errors

- In process (for example environmental monitoring excursions)
- Finished product (failure of potency or sterility testing)
- Field complaints

USP <797> states “When action levels are exceeded, an investigation into the source of the contamination shall be conducted.” (see section Environmental Monitoring - Action Limits, Documentation, and Data Evaluation) and “Positive sterility test results should prompt a rapid and systematic investigation of aseptic technique, environmental control, and other sterility assurance controls to identify sources of contamination and correct problems in the methods or processes” (see section Finished Preparation Release Checks and Tests – Sterility Tests).



The
Microbiology
NETWORK

21

Control of Pyrogenic Contamination

USP <797> addresses this specific topic in “Verification of Compounding Accuracy and Sterility – Depyrogenation by Dry Heat where it is stated “The description of the dry heat depyrogenation cycle and duration for specific load items shall be included in written documentation in the compounding facility. The effectiveness of the dry heat depyrogenation cycle shall be verified using endotoxin challenge vials (ECVs). The bacterial endotoxin test should be performed on the ECVs to verify the cycle is capable of achieving a 3 log reduction in endotoxin.

Bacterial Endotoxin Levels are addressed as a finished product specification in the <797> section “Finished Preparation Release Checks and Tests – Bacterial Endotoxin (Pyrogen) Testing”



The
Microbiology
NETWORK

22

483 Topic Issue	Frequency
Stability Program	82.5%
Validation of Sterilization - Media Fills	80.7%
Inadequate/ Improper Environmental Monitoring	80.7%
SOPs to Prevent Microbial Contamination Non-existent or Not Followed	73.7%
Inadequate Gowning	70.2%
Lab Procedures: Testing/ Contract Lab Control	68.4%
Batch Release	64.9%
Inadequate Cleaning/ Disinfection	54.4%
Control of Equipment	52.6%
Inadequate Facility / Smoke Studies	49.1%
Investigations	47.4%
Control of Pyrogenic Contamination	40.4%
QAU Not Effective/ Production SOPs not followed/effective	38.6%
Separation of Clean and Dirty Operations/Storage of Materials	29.8%
Inadequate raw material control	26.3%
Container Preparation	19.3%
SOP/Control of Production	14.0%
Safeguard Against Penicillin/ Cephalosporine Cross Contamination	12.3%
Records not Available	14.0%
Labelling Issues	7.0%
Personnel not Trained/ Inadequate	8.8%
Obvious Product Contamination (Micro/Particulate)	5.3%
Change Control	3.5%

Microbiology NETWORK 23

Overview of Presentation

- The Recent Events
- GCP and GMP Basics – the 483 Review
- H.R. 3204 – Outsourcing Facility
- Preparation for the Future

H.R. 3204

Establishes “Outsourcing Facilities”

- Pay an annual registration fee of \$15,000
- Not be allowed to compound drugs that
 - Have had their approval withdrawn
 - Are on a safety list that FDA would be charged with creating and maintaining
 - Or are likely to lead to adverse events.
- The drugs would have to be clearly labelled as a compounded drug.
- Be required to report twice a year on the drugs compounded during the last 6 months. Adverse events would need to be reported to FDA within 15 days.



The
Microbiology
NETWORK

25

H.R. 3204 (cont)

Establishes “Outsourcing Facilities”

- Be required to submit to FDA inspections on a schedule that would be determined by FDA considering
 - Facility’s recall history
 - Facility’s compliance history
 - The risk of the drugs compounded by the facility.
- Be subject to significant penalties for failing to pay registration or reinspection fees.



The
Microbiology
NETWORK

26

H.R. 3204 (cont)

Pharmacies that do not register as outsourcing facilities may be prohibited from compounding drug products without a valid prescription.

Overview of Presentation

- The Recent Events
- GCP and GMP Basics – the 483 Review
- H.R. 3204 – Outsourcing Facility
- Preparation for the Future

Know the Requirements

- USP <797> is under revision
- Outsourcing Facilities may face a combination of GCP and GMP
 - Review 21 CFR 211
 - Know USP <795>, <797> and <1163>
 - Have your facility in a state of control
 - Have your processes in a state of control
 - Have your testing and stability in line with expectations

Facility Control

- Physical Barriers/Design
- HVAC
- Water
- Cleaning
- Sanitization
- Monitoring

Process Control

- Incoming materials
 - Actives
 - Excipients
 - Water
 - Containers
- Equipment
- Process steps
- Hold times
- Filling conditions



The
Microbiology
NETWORK

31

Testing

- Performed in-house
- Contracted
 - You are responsible for the quality of the work you contract – it is your preparation (product)
- Sterility Testing a particular concern



The
Microbiology
NETWORK

32

Sterility Testing

- Two separate tests
 - Membrane Filtration
 - Direct Transfer
- 20 Units, 2 media & temperatures
- Requires Growth
 - Incubation period - 14 days



Moldenhauer, J and S. Sutton. 2004. Towards an Improved Sterility Test. *PDA J of Science and Technology* 58(6):284-286.

Membrane Filtration

- Filter required amount of product through two filters
- Neutralize/Rinse
 - 3 100 mL volumes suggested
 - Formulations for dilution fluids suggested
- One filter into Soybean Casein Digest Broth (SCDB or TSB) – incubate at 20-25°C for 14 days
- One filter into Fluid Thioglycollate Medium (FTM) – incubate at 30-35°C for 14 days

Direct Inoculation

- Place required amount of product into sufficient recovery medium (with neutralizers?)
 - Soybean Casein Digest Broth (SCDB or TSB)
 - incubate at 20-25°C for 14 days
 - Fluid Thioglycollate Medium (FTM) – incubate at 30-35°C for 14 days

Method Suitability Test

Can we neutralize any antimicrobial properties of the medication?

Use specified challenge organisms

Use specified total amounts of products

Review of Presentation

- The Recent Events
- GCP and GMP Basics – the 483 Review
- H.R. 3204 – Outsourcing Facility
- Preparation for the Future



37



Thank you for your attention

Scott Sutton, Ph.D.

scott.sutton@microbiol.org

+1 585-298-0767 (cell)

<http://www.linkedin.com/in/scottvwsutton>

@MicrobiologyNet

www.microbiol.org